EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy

Yunhao Chen, Xingchen Ding, Xinbin Bai, Zihan Zhou, Yu Liu, Xianbin Zhang, Jinming Yu, Man Hu

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110329 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Yunhao Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong University Cancer Center, Jinan, Shandong 250117, China; Department of Radiation Oncology, Shandong Cancer…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Head and Neck Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica, Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have previously demonstrated their efficacy and safety in various solid tumors, and with the growing interest in the application of ICIs in head and neck squamous cell carcinoma (HNSCC), various data have been reported. Mechanistically, HNSCC cells express programmed death ligand 1 (PD-L1), which binds to its receptor programmed death 1 (PD-1). Immune escape plays a key role in disease initiation and progression. Studying the abnormal activation of related pathways of PD-1/PD-L1 will help to understand the way of immunotherapy and find the advantageous population of immunotherapy. How to reduce HNSCC-related mortality and morbidity in this process has promoted the search for new therapeutic strategies, especially in the era of immunotherapy. PD-1 inhibitors have demonstrated significant prolongation of survival in recurrent/metastatic (R/M) HNSCC with a favorable safety profile. It also holds great promise in locally advanced (LA) HNSCC, where numerous studies are underway. Although immunotherapy has made great progress in HNSCC research, there are still many challenges. Therefore, in the review, we conducted an in-depth study on the expression of PD-L1 and the regulatory, immunosuppressive mechanisms caused by PD-L1, especially in head and neck squamous cell carcinoma, which is different from other tumors. And further summarize the situation, challenges and development trends of PD-1 and PD-L1 blockade in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorHead and Neck NeoplasmsHumansSquamous Cell Carcinoma of Head and NeckB7-H1 AntigenNeoplasm Recurrence, LocalImmunotherapyImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

ImmunotherapyLA HNSCCPD-1/PD-L1 inhibitorsR/M HNSCC

Substanzen

Programmed Cell Death 1 ReceptorB7-H1 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, Shandong University Cancer Center, Jinan, Shandong 250117, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandon…
  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.
  • Department of Radiation Oncology, Tumor Hospital of Jining, Jining, Shandong 272007, China.
  • Department of Oncology, Weifang Medical University, Weifang, Shandong 261053, China.
  • Department of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Shenzhen University General Hospital, Shenzhen University, Shenzhen,…
  • Department of Radiation Oncology, Shandong University Cancer Center, Jinan, Shandong 250117, China; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital…

Förderung

  • National Natural Science Foundation of China
  • China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica
  • Chinese Academy of Medical Sciences
  • Natural Science Foundation of Shandong Province
  • Jinan Science and Technology Bureau

Zitieren

APA

Chen, Y., Ding, X., Bai, X., Zhou, Z., Liu, Y., Zhang, X., Yu, J., & Hu, M. (2023). The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110329

Vancouver

Chen Y, Ding X, Bai X, Zhou Z, Liu Y, Zhang X, et al. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110329

BibTeX
@article{Chen2023,
  author = {Chen, Yunhao and Ding, Xingchen and Bai, Xinbin and Zhou, Zihan and Liu, Yu and Zhang, Xianbin and Yu, Jinming and Hu, Man},
  title = {The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110329}
}
Kostenlos starten →